Immuneering (IMRX) Amortization of Deferred Charges (2020 - 2026)
Immuneering's (IMRX) quarterly Amortization of Deferred Charges came in at $91760.0 in Q1 2026, up 10.31% year-on-year from $83183.0 in Q1 2025, and up 2.59% quarter-over-quarter from $89443.0 in Q4 2025.
Immuneering (IMRX) Amortization of Deferred Charges (2020 - 2026) Analysis & Trends
Immuneering's Amortization of Deferred Charges history runs 7 years deep, the most recent figure standing at $91760.0 for Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges rose 10.31% year-over-year to $91760.0 in Q1 2026; TTM through Mar 2026 was $353680.0, a 10.04% increase from a year earlier, with the FY2025 full-year figure at $345103.0, up 5.09% from the prior year.
- Amortization of Deferred Charges grew to $91760.0 in Q1 2026 per IMRX's latest filing, from $89443.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $144821.0 in Q1 2022 and bottomed at $77632.0 in Q2 2024.
- The 5-year median for Amortization of Deferred Charges is $90155.0 (2024), against an average of $99813.9.
- Across the five-year window, Amortization of Deferred Charges surged 478.66% in 2022 and fell 28.09% in 2024, its largest moves.
- Year by year, Amortization of Deferred Charges stood at $105097.0 in 2022, then dropped by 16.13% to $88145.0 in 2023, then dropped by 7.87% to $81212.0 in 2024, then increased by 10.14% to $89443.0 in 2025, then increased by 2.59% to $91760.0 in 2026.
- Per Business Quant, the three latest IMRX Amortization of Deferred Charges figures stand at $91760.0 (Q1 2026), $89443.0 (Q4 2025), and $87274.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Immuneering | 283.85 Mn | 283.85 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 91,760.00 |
| Mar 31, 2026 | 91,760.00 |
| Dec 31, 2025 | 89,443.00 |
| Dec 31, 2025 | 89,443.00 |
| Sep 30, 2025 | 87,274.00 |
| Sep 30, 2025 | 87,274.00 |
| Jun 30, 2025 | 85,203.00 |
| Jun 30, 2025 | 85,203.00 |
| Mar 31, 2025 | 83,183.00 |
| Mar 31, 2025 | 83,183.00 |
| Dec 31, 2024 | 81,212.00 |
| Dec 31, 2024 | 81,212.00 |
| Sep 30, 2024 | 79,378.00 |
| Sep 30, 2024 | 79,378.00 |
| Jun 30, 2024 | 77,632.00 |
| Jun 30, 2024 | 77,632.00 |
| Mar 31, 2024 | 90,155.00 |
| Mar 31, 2024 | 90,155.00 |
| Dec 31, 2023 | 88,145.00 |
| Dec 31, 2023 | 88,145.00 |